Company Description
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient.
In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives.
Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection.
The company’s customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients.
Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jun 20, 2019 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 229 |
| CEO | Christopher Hall |
Contact Details
Address: 6600 Dumbarton Circle Fremont, California 94555 United States | |
| Phone | 650 752 1300 |
| Website | personalis.com |
Stock Details
| Ticker Symbol | PSNL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001527753 |
| CUSIP Number | 71535D106 |
| ISIN Number | US71535D1063 |
| Employer ID | 27-5411038 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Christopher M. Hall | President, Chief Executive Officer and Director |
| Aaron L. Tachibana | Chief Financial Officer and Chief Operating Officer |
| Dr. Richard Chen M.D., M.S. | Executive Vice President of Research & Development and Chief Medical Officer |
| Dr. Russ B. Altman M.D., Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
| Dr. Euan Angus Ashley DPHIL, FRCP, M.D., Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
| Dr. Michael P. Snyder Ph.D. | Co-Founder and Member of Clinical and Scientific Advisory Board |
| Stephen M. Moore J.D. | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. Christian Haudenschild Ph.D. | Senior Vice President of Genomic Laboratory Operations |
| Stephane Mouradian Ph.D. | Senior Vice President of Business Development |
| Deepshikha Bhandari | Senior Vice President of Regulatory, Quality and Clinical Compliance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2025 | EFFECT | Notice of Effectiveness |
| Apr 3, 2025 | ARS | Filing |
| Apr 3, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 3, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |